Drug intelligence / Profile preview

ABO1105B

Development stage: Unknown
Lead developer: Abogen Bioscience
Modality: mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

ABO1105B is a lyophilized mRNA vaccine candidate developed by Abogen Biosciences for the prevention of respiratory syncytial virus (RSV) infection and associated lower respiratory tract disease (LRTD). The vaccine utilizes mRNA technology to encode a viral antigen, typically the RSV fusion (F) protein, to induce protective immune responses. A key feature of ABO1105B is its lyophilized (freeze-dried) formulation, which is designed to enhance thermal stability and simplify cold-chain logistics compared to standard liquid mRNA vaccines. It is currently being evaluated in Phase II clinical trials in China, specifically targeting adults aged 50 years and older.

Targets

RSV F (Respiratory syncytial virus fusion protein)

Beyond the preview

Go deeper on ABO1105B.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ABO1105B.

Explore the full profile